Business
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection. The USAN, cons
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection.","length":490,"tagName":"p"},{"type":"text","content":"The USAN, consisting of members from the Food and Drug Administration (FDA), American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA), is responsible for developing simple, informative and unique nonproprietary (generic) drug names.","length":292,"tagName":"p"},{"type":"text","content":"“The adoption of pevifoscorvir sodium, or pevy, marks the first generic name for a compound at Aligos,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “As we continue to progress our Phase 2 B-Supreme study, we look forward to adopting this new name. This milestone showcases our continued innovation in the liver and viral disease space and reinforces our commitment to improving patient outcomes.”","length":458,"tagName":"p"},{"type":"text","content":"Generic drug names like pevifoscorvir sodium ensure consistent identification. Standardized naming also supports international recognition and transparency across markets.","length":171,"tagName":"p"},{"type":"text","content":"About pevifoscorvir sodiumPevifoscorvir sodium (formerly known as ALG-000184) was derived from initial IP licensed from the laboratory of Dr. Raymond Schinazi at Emory University, which was further optimized...